Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Swapna Thomas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, Research Complex, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, Antibodies, Viral, SARS-CoV-2, Immunoglobulin G. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by partial funds from QU..
Abstract (Originalsprache)
This study evaluated the potential for antibody‐dependent enhancement (ADE) in serum samples from patients exposed to Middle East respiratory syndrome coronavirus (MERS‐CoV). Furthermore, we evaluated the effect of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination on ADE in individuals with a MERS infection history. We performed ADE assay in sera from MERS recovered and SARS‐CoV‐2‐vaccinated individuals using BHK cells expressing FcgRIIa, SARS‐CoV‐2, and MERS‐CoV pseudoviruses (PVs). Further, we analyzed the association of ADE to serum IgG levels and neutralization. Out of 16 MERS patients, nine demonstrated ADE against SARS‐CoV‐2 PV, however, none of the samples demonstrated ADE against MERS‐CoV PV. Furthermore, out of the seven patients exposed to SARS‐CoV‐2 vaccination after MERS‐CoV infection, only one patient (acutely infected with MERS‐CoV) showed ADE for SARS‐CoV‐2 PV. Further analysis indicated that IgG1, IgG2, and IgG3 against SARS‐CoV‐2 S1 and RBD subunits, IgG1 and IgG2 against the MERS‐CoV S1 subunit, and serum neutralizing activity were low in ADE‐positive samples. In summary, samples from MERS‐CoV‐infected patients exhibited ADE against SARS‐CoV‐2 and was significantly associated with low levels of neutralizing antibodies. Subsequent exposure to SARS‐CoV‐2 vaccination resulted in diminished ADE activity while the PV neutralization assay demonstrated a broadly reactive antibody response in some patient samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research Center, Research Complex, Qatar University, Doha, Qatar.
- Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha, Qatar.
- QU Health, Qatar University, Doha, Qatar.
- Department of Biomedical Science, College of Health Sciences-QU Health, Qatar University, Doha, Qatar.
- College of Medicine-QU Health, Qatar University, Doha, Qatar.
- Medical Intensive Care Unit, Hamad Medical Corporation, Doha, Qatar.
ORCID-Profile: Hadeel T Zedan, Laith J Abu Raddad, Gheyath K Nasrallah, Hadi M Yassine
Förderung
- This study was supported by partial funds from QU.
Zitieren
APA
Thomas, S., Smatti, M. K., Alsulaiti, H., Zedan, H. T., Eid, A. H., Hssain, A. A., Abu Raddad, L. J., Gentilcore, G., Ouhtit, A., Althani, A. A., Nasrallah, G. K., Grivel, J. C., & Yassine, H. M. (2024). Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens. Journal of Medical Virology. https://doi.org/10.1002/jmv.29628
Vancouver
Thomas S, Smatti MK, Alsulaiti H, Zedan HT, Eid AH, Hssain AA, et al. Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens. Journal of Medical Virology. 2024. doi:10.1002/jmv.29628
BibTeX
@article{Thomas2024,
author = {Thomas, Swapna and Smatti, Maria K and Alsulaiti, Haya and Zedan, Hadeel T and Eid, Ali H and Hssain, Ali A and Abu Raddad, Laith J and Gentilcore, Giusy and Ouhtit, Allal and Althani, Asmaa A and Nasrallah, Gheyath K and Grivel, Jean-Charles and Yassine, Hadi M},
title = {Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29628}
}
EUVIMED